Bicyclol
118159-48-1COC(=O)c1cc(OC)c2c(c1-c1c(CO)cc(OC)c3c1OCO3)OCO2KXMTXZACPVCDMH-UHFFFAOYSA-NBicyclol is under investigation in clinical trial NCT02944552 (The Multi Center, Randomized, Double-blind, Positive Controlled Study of Bicyclol in the Treatment of Acute DILI).
118159-48-1DTXSID30152026CHEMBL482035安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。
Warning
H400 (100%): Very toxic to aquatic life [Warning Hazardous to the aquatic environment, acute hazard]
P273, P391, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 39 reports by companies from 2 notifications to the ECHA C&L Inventory.
説明Bicyclol is a hepatoprotective agent. It has antiviral activity against hepatitis B (HBV), reducing viral DNA and the secretion of the HBV antigens HBsAg and HBeAg by 59 and 35%, respectively, in infected 2.2.15 HepG2 cells. In vivo, bicyclol reduces duck HBV (DHBV) DNA in DHBV-infected ducks at doses ≥0.4 g/kg. It also reduces the expression of TNF-α and the accumulation of lymphocytes in the liver in a mouse model of liver injury induced by concanavalin A . Oral administration of bicyclol prior to injection of diethylnitrosamine (DEN) and phenobarbital (PB; Item Nos. 9001494 | 20987) prevents formation of DEN/PB-induced hepatocellular carcinomas. It also reduces liver fibrosis in a rat model of bile duct ligation-induced hepatic fibrosis.